Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and myocardial effects of albiglutide in NYHA II/III heart failure
2010-020352-59Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Albiglutide with Placebo (2 arms). Primary endpoints: Myocardial glucose utilization by FDG-PET and Left ventricular function by echocardiography. Started Jun 2010; status: completed.
02
Drugs
albiglutide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2010-020352-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020352-59.